Trial Profile

Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study for the Safety, Tolerability, and Efficacy of IV MTP-131 for Mitochondrial Myopathy in Genetically Confirmed Mitochondrial Disease

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2026 According to Stealth BioTherapeutics media release, Stealth BioTherapeutics is now called Mighty Therapeutics.
02 Mar 2018 Results published in the Neurology
12 Sep 2016 According to Stealth BioTherapeutics media release, the company hopes to use results of this study and MMPOWER 2 study to engage in discussions with regulators to develop the design for a Phase 3 trial in primary mitochondrial disease

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com